Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma

Adarsh Das, Andrew Dean, Tim Clay

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


A woman in her mid-70s with metastatic pancreatic adenocarcinoma presented with fatigue, nausea and bilateral leg swelling, 4 days after an intravenous gemcitabine infusion. Additional examination and laboratory tests showed mild hypertension, low haemoglobin, high lactate dehydrogenase, low platelet count and high serum creatinine. The patient was subsequently diagnosed with haemolytic uraemic syndrome (HUS), and gemcitabine administration was immediately ceased. The patient received a 5-day course of methylprednisolone, with a full recovery being made 10 days after diagnosis. Clinicians should be aware of the rare but serious complication of gemcitabine-induced HUS (GiHUS), as early diagnosis and management, which includes prompt discontinuation of gemcitabine, are crucial in promptly resolving this condition. This case report describes one treatment that can be used for the treatment of GiHUS, while briefly covering some other novel treatments that have been described in other studies.

Original languageEnglish
Article numbere228363
JournalBMJ Case Reports
Issue number4
Publication statusPublished - 1 Apr 2019


Dive into the research topics of 'Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this